Dr. Christopher Trevino, MD – Evanston ...

Dr. Christopher R. Trevino

Claim this profile

Tulane University Health Sciences Center

Studies Brain Tumor
Studies Glioblastoma
12 reported clinical trials
39 drugs studied

Area of expertise

1

Brain Tumor

Christopher R. Trevino has run 5 trials for Brain Tumor. Some of their research focus areas include:

MET positive
MET negative
Stage IV
2

Glioblastoma

Christopher R. Trevino has run 4 trials for Glioblastoma. Some of their research focus areas include:

MET negative
MET positive
IDH negative

Affiliated Hospitals

Image of trial facility.

Tulane University Health Sciences Center

Image of trial facility.

NorthShore University HealthSystem-Evanston Hospital

Clinical Trials Christopher R. Trevino is currently running

Image of trial facility.

Radiation Therapy vs Observation

for Meningioma

This trial studies if radiation therapy helps prevent the return of grade II meningioma after surgery. Radiation therapy uses powerful x-rays to destroy any leftover cancer cells. The goal is to see if this improves patient outcomes compared to just monitoring them. Radiation therapy has shown success in stabilizing tumor growth and reducing recurrence risk.

Recruiting

2 awards

Phase 3

12 criteria

Image of trial facility.

Relatlimab + Nivolumab

for Recurrent Glioblastoma

This phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with glioblastoma that has come back after a period of improvement (recurrent). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's deoxyribonucleic acid and may kill tumor cells. Giving relatlimab and nivolumab may be safe, tolerable, and/or effective compared to standard of care lomustine in treating patients with recurrent glioblastoma.

Recruiting

1 award

Phase 2

15 criteria

More about Christopher R. Trevino

Clinical Trial Related

9 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Christopher R. Trevino has experience with

  • Nivolumab
  • Ipilimumab
  • Lomustine
  • Radiation Therapy
  • Cabozantinib
  • Berubicin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Christopher R. Trevino specialize in?

Is Christopher R. Trevino currently recruiting for clinical trials?

Are there any treatments that Christopher R. Trevino has studied deeply?

What is the best way to schedule an appointment with Christopher R. Trevino?

What is the office address of Christopher R. Trevino?

Is there any support for travel costs?